PT - JOURNAL ARTICLE AU - Funakoshi, Yohei AU - Yakushijin, Kimikazu AU - Ohji, Goh AU - Hojo, Wataru AU - Sakai, Hironori AU - Takai, Ryo AU - Nose, Taku AU - Ohata, Shinya AU - Nagatani, Yoshiaki AU - Koyama, Taiji AU - Kitao, Akihito AU - Nishimura, Meiko AU - Imamura, Yoshinori AU - Kiyota, Naomi AU - Harada, Kenichi AU - Tanaka, Yugo AU - Mori, Yasuko AU - Minami, Hironobu TI - Safety and Immunogenicity of the COVID-19 Vaccine BNT162b2 in Patients Undergoing Chemotherapy for Solid Cancer AID - 10.1101/2021.10.25.21265324 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.25.21265324 4099 - http://medrxiv.org/content/early/2021/10/25/2021.10.25.21265324.short 4100 - http://medrxiv.org/content/early/2021/10/25/2021.10.25.21265324.full AB - Background Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing chemotherapy for solid cancers in Japan have not been reported.Methods We investigated the safety and immunogenicity of BNT162b2 in 41 patients undergoing chemotherapy for solid cancers and in healthy volunteers who received 2 doses of BNT162b2. We evaluated serum IgG antibody titers for S1 protein by ELISA at pre-vaccination, prior to the second dose and 14 days after the second vaccination in 24 cancer patients undergoing cytotoxic chemotherapy (CC group), 17 cancer patients undergoing immune checkpoint inhibitor therapy (ICI group) and 12 age-matched healthy volunteers (HV group). Additionally, inflammatory cytokine levels were compared between the HV and ICI groups at pre and the next day of each vaccination.Results Anti-S1 antibody levels were significantly lower in the ICI and CC groups than in the HV group after the second dose (median optimal density: 0.241 [0.063-1.205] and 0.161 [0.07-0.857] vs 0.644 [0.259-1.498], p = 0.0024 and p < 0.0001, respectively). Adverse effect profile did not differ among the three groups, and no serious adverse event occurred. There were no differences in vaccine-induced inflammatory cytokines between the HV and ICI groups.Conclusion Although there were no significant differences in adverse events in three groups, antibody titers were significantly lower in the ICI and CC groups than in the HV group. Further protection strategies should be considered in cancer patients undergoing CC or ICI.Mini abstract Titers of anti-S1 antibody after the second dose of BNT162b2 were significantly lower in patients with solid tumors undergoing active anticancer treatment than in the healthy volunteers.Competing Interest StatementHironobu Minami has received research grants and honoraria from Pfizer. Wataru Hojo and Hironori Sakai are employed by Cellspect Co., Ltd. Kimikazu Yakushijin has received honoraria from Pfizer. The other authors declare no potential conflicts of interest.Funding StatementThis study was funded by Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Kobe University Hospital Ethics Committee (No. B2056714) and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent for this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.